Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma

British Journal of Dermatology

Volumn 164, Issue 1, 2011, Pages 135-140

  Wang, L ^a,b,c   Xiang, Y N ^d   Zhang, Y H ^d   Tu, Y T ^a   Chen, H X ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MIRIAM HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 8A ANTIBODY; CD10 ANTIBODY; CD34 ANTIGEN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 GENE ANTIBODY; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; STROMELYSIN 3; STROMELYSIN 3 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 78650486906     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10050.x     Document Type: Article

References (33)

1. Kim HJ, Lee JY, Kim SH, et al. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 2007; 157: 319-24.
2. Mori T, Misago N, Yamamoto O, et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. J Dermatol 2008; 35: 419-25. (Pubitemid 351977689)
3. Goldblum JR, Tuthill RJ,. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997; 19: 147-53.
4. Abenoza P, Lillemoe T,. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993; 15: 429-34. (Pubitemid 23303044)
5. Pursley HG, Williford PM, Groben PA, White WL,. CD34-positive eruptive fibromas. J Cutan Pathol 1998; 25: 122-5.
6. Hsi ED, Nickoloff BJ,. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. J Dermatol Sci 1996; 11: 1-9.
7. Kahn HJ, Fekete E, From L,. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Hum Pathol 2001; 32: 50-6. (Pubitemid 32150628)
8. Li N, McNiff J, Hui P, et al. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity. Am J Dermatopathol 2004; 26: 267-72. (Pubitemid 38989021)
9. Kubo M, Ihn H, Yamane K, Tamaki K,. The expression levels and the differential expression of transforming growth factor-β receptors in dermatofibroma and dermatofibrosarcoma protuberans. Br J Dermatol 2006; 154: 919-25.
10. Calikoglu E, Augsburger E, Chavaz P, et al. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. J Cutan Pathol 2003; 30: 185-9. (Pubitemid 36428427)
11. Adler N, Tsabari C, Sulkes J, et al. Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans. J Cutan Pathol 2008; 35: 532-5. (Pubitemid 351661544)
12. Sasaki M, Ishida T, Horiuchi H, MacHinami R,. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression. Pathol Int 1999; 49: 799-806. (Pubitemid 29513294)
13. Toyozawa S, Yamamoto Y, Ishida Y, et al. Immunohistochemical analysis of CXCR4 expression in fibrohistiocytic tumors. Acta Histochem Cytochem 2010; 43: 45-50.
14. Xiaoli Z, Qinhe F,. Expression of retinoic acid receptor beta in dermatofibrosarcoma protuberans. J Cutan Pathol 2009; 36: 1141-5.
15. Fullen DR, Reed JA, Finnerty B, McNutt NS,. S100A6 expression in fibrohistiocytic lesions. J Cutan Pathol 2001; 28: 229-34. (Pubitemid 32391822)
16. Bellam N, Pasche B,. TGF-beta signaling alterations and colon cancer. Cancer Treat Res 2010; 155: 85-103.
17. Shinto O, Yashiro M, Kawajiri H, et al. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 2010; 102: 844-51.
18. Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005; 96: 261-8. (Pubitemid 40209374)
19. Durmus T, LeClair RJ, Park KS, et al. Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1). Gene Expr Patterns 2006; 6: 935-40. (Pubitemid 44309445)
20. LeClair RJ, Durmus T, Wang Q, et al. Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res 2007; 100: 826-33. (Pubitemid 46555687)
21. LeClair R, Lindner V,. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling. Trends Cardiovasc Med 2007; 17: 202-5. (Pubitemid 47089010)
22. Tang L, Dai DL, Su M, et al. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 2006; 12: 3716-22. (Pubitemid 44000252)
23. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7: 55. (Pubitemid 46605012)
24. Goncharuk V, Mulvaney M, Carlson JA,. Bednar tumor associated with dermal melanocytosis: melanocytic colonization or neuroectodermal multidirectional differentiation. J Cutan Pathol 2003; 30: 147-51. (Pubitemid 36384861)
25. Sellheyer K, Nelson P, Krahl D,. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells. Br J Dermatol 2009; 161: 1317-22.
26. Yamamoto S, Nishimura O, Misaki K, et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 2008; 15: 23-36. (Pubitemid 351895602)
27. Kelley MW,. Leading Wnt down a PCP path: Cthrc1 acts as a coreceptor in the Wnt-PCP pathway. Dev Cell 2008; 15: 7-8.
28. Nishio J, Iwasaki H, Ohjimi Y, et al. Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study. Cancer Genet Cytogenet 2002; 132: 102-8. (Pubitemid 34170866)
29. Breuninger H, Sebastian G, Garbe C,. Dermatofibrosarcoma protuberans-an update. J Dtsch Dermatol Ges 2004; 2: 661-7. (Pubitemid 39381768)
30. Wang WL, Patel KU, Coleman NM, et al. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin. Am J Dermatopathol 2010; 32: 149-53.
31. LeClair RJ, Wang Q, Benson MA, et al. Intracellular localization of Cthrc1 characterizes differentiated smooth muscle. Arterioscler Thromb Vasc Biol 2008; 28: 1332-8.
32. Quigley EA, Marghoob AA, Busam KJ, Chen CS,. A firm red-brown plaque on the arm. Dermatofibrosarcoma protuberans (DFSP), pigmented variant (Bednar tumor). Arch Dermatol 2009; 145: 589-94.
33. McAllister JC, Recht B, Hoffman TE, Sundram UN,. CD34+ pigmented fibrous proliferations: the morphologic overlap between pigmented dermatofibromas and Bednar tumors. Am J Dermatopathol 2008; 30: 484-7.